Pfizer: A Decade’s Bet for the Astute Investor

Behold the pharmaceutical colossus that forgot to duck when the market swung its bat. First came the post-pandemic comedown-a hangover from vaccine euphoria. Then patent cliffs loomed like Dickensian debt collectors. Even tariffs, those international gamekeepers, threatened to poach profits. But Pfizer, ever the chess player, now reveals a gambit.







